Sherwood
Wednesday Jul.23, 2025

đź‘€ Even Citadel Securities is watching

snacks hero image 7/23
(Apu Gomes/Getty Images)
Presented by

Hey Snackers,

We mentioned in an earlier edition that our dreams of cane-sugar-filled Coke in the US may soon be reality and lo and behold, yesterday Coca-Cola confirmed that it’s soon adding just such a sugar-filled cola to its lineup! Will this further cement the company’s hold on soft drink market share? Call us crazy, but Pepsi’s new Prebiotic Cola just doesn’t have the same buzz.

The S&P 500 closed at another record high, but what everyone was really watching yesterday were the meme stocks. Sure, the S&P 500 inched up less than 0.1% to close at a fresh record, the Russell 2000 enjoyed a 0.8% advance, and the tech-heavy Nasdaq 100 fell 0.5%, but really the stocks outside the benchmark index were where the most interesting action was. More on that below. 

Do we have your attention?

Citadel Securities knows what’s up. It’s the designated market maker on the NYSE and, per the company, represents about 62% of listings on the exchange. And it’s seeing something it hasn’t seen in years.

  • The trading giant is keeping a “close eye” on the same thing we’re keeping a close eye on: retail traders driving eye-popping moves in the likes of Opendoor Technologies, which traded more than Meta on Monday only to fall 10% on Tuesday after a real heater, a six-session streak.

  • On Monday, trades of 521 million shares in Opendoor took place on the ask side (the lowest price a seller is willing to accept, indicating a motivated buyer) versus volumes of 480 million on the bid. On Tuesday, volumes on bid side outnumbered those on the ask, per Bloomberg data. 

  • And then there’s Kohl’s, which doubled minutes into the session on Tuesday and set a new record for daily volumes traded less than 25 minutes after the market opened, before paring much of its gains.

“Echoing our colleagues in institutional derivatives this morning, the current level of retail bullishness is something to keep a close eye on,” Citadel Securities’ Thomas Sozzi wrote. “In cash equity space, retail clients on our platform have been net buyers for the past 18 trading sessions in a row! This bullish streak hasn’t been seen on our platform in over 3 years.”

The Takeaway

Things are getting wild out there. Again, take Opendoor for example. The options flows were still overwhelmingly tilted toward calls — calls outnumbered puts by about 1.9:1 Tuesday versus roughly 2:1 on Monday — but the most active option traded on Opendoor was a put with a strike price of $2.50 that expires on Friday. When flows are more of the story than fundamentals, it’s this relatively boring tallying of motivated buying versus motivating selling that can give a clue as to how much momentum a move has and whether it’s at risk of reversing.

Read more.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. Citadel Securities has a business relationship with Robinhood.)

Presented by HeartSciences
HeartSciences branded imagery - digital screen showing a heart and chart in the background

This Listed Healthcare Company Is Offering Unlisted Preferred Stock… for $3.50

While this company’s stock trades on the Nasdaq (ticker: HSCS), you won’t find this offering there.

HeartSciences is a leader in AI technology that makes heart disease easier to detect on the frontlines. 

Their cloud-based software platform is designed for use with existing ECG devices without the need for new hardware — which could have applications for the 300 million ECGs performed globally every year.  

Shares of HSCS common stock have closed as high as $5.73 this month and its closing price on 7/21 was $4.03.1

But through their special unit offering, you can get a share of unlisted preferred stock for $3.50 — which can be converted into a share of Nasdaq-traded stock at any time — plus a warrant.2

HeartSciences is also targeting FDA submission this summer,3 making now a key moment to invest. 

Invest in HeartSciences unit offering  now at $3.50/unit price.4

1 52-week range for HSCS is $2.36 to $6.47 as of 7/21/25.

Ethereum ETFs turn 1

Today marks the one-year anniversary of the first ethereum ETF listing in the US. How fast these little funds grow! In fact, ethereum ETFs now hold $15.7 billion in assets under management and the pace of adoption has picked up recently, buoyed by several factors including the GENIUS Act’s passage. Last week, ethereum ETFs saw a record $2.12 billion in inflows, nearly double its previous record of $1.2 billion, leading the funds to their best month on record. And July’s not even over! 

The second-place crypto (in terms of market cap, behind bitcoin) had a second-place ETF start (also behind bitcoin, whose ETF celebrated its birthday earlier this year). While ethereum may never dominate the space as bitcoin has and does, it does have some unique factors that may help it catch up, quick:

  • Ethereum will benefit greatly from the growth in tokenization and the regulatory clarity surrounding stablecoins through the GENIUS Act. The stablecoin market cap stands at $262 billion, and stablecoins on the ethereum blockchain take the lion’s share with a $130 billion piece of the pie, which will likely grow from here. 

  • Staking also has a part to play. As of now, ethereum ETFs are not allowed to stake, or lock up their tokens to secure the network and earn rewards. (Think of it as earning interest for committing your cash to a CD.) If the SEC allows staking within ETFs, it could put the billions in these ETFs to work. As the CEO of Blueprint Finance told us, “Once institutions can access both price appreciation and network rewards through a regulated wrapper, that changes the entire institutional conversation.”

The Takeaway

It’s not just ethereum ETFs that are having a moment, but ethereum overall. From a wave of ethereum treasury companies like SharpLink and BitMine popping up to Cathie Wood’s Ark Invest shifting its portfolio to increase exposure to ethereum and the asset itself hitting price levels it hasn’t seen in many months, it’s been a good run for the asset, and it doesn’t seem to be slowing down.

Read more.

The Best Thing We Read Today

From God to Gordon Gekko: How greed became good

Paul Vigna’s “The Almightier” asks the question: how did the pursuit of wealth evolve from being the root of all evil to not just a virtue, but the central incentive of our entire culture? He sat down with Sherwood News to discuss why Western ideas about money are outdated and if there’s any societal benefit to crypto. 

Read our first Talk Your Book feature.

Yesterday’s Big Daily Movers

What Else We're Snackin'

  • Here’s how much traders think Google and Tesla are poised to move after today’s earnings reports 

  • And here’s the most insane trading day for Opendoor yet, charted

  • But Wall Street is starting to quietly warn about the stock market

  • Meanwhile, Morgan Stanley forecast a $70 billion boost for megacap tech companies from the One Big Beautiful Bill Act

  • Over in Canada, a tiny biotech company bought 2,000 shares of GameStop for an unusual reason

Snack Fact Of The Day

Tariffs cost GM a reported $1.1 billion last quarter.

Today's Events

W

Earnings expected from Alphabet, Tesla, AT&T, IBM, T-Mobile, Chipotle, Hasbro, Freeport-McMoRan, GE Vernova, General Dynamics, Hilton Worldwide, CME Group, and CSX

2 The special unit offering is one share of convertible preferred stock (convertible into Nasdaq freely tradable common stock at any time) and one warrant to purchase an additional share of Nasdaq tradable common stock at a fixed price exercisable at any time for three years. Minimum investment is $675 (193 units). See prospectus for further details. 

3  A plan to file for FDA approval does not mean that the filing will occur. In addition, a filing for FDA approval is no guarantee of an actual FDA approval.

4 The minimum investment is $675 (193 units).This is a paid advertisement for HeartSciences’ Regulation A+ offering of Series D Convertible Preferred Stock and a Warrant. Please read the offering circular and related risks at HeartSciences website. Before making any investment, you are urged to read the prospectus carefully for a more complete understanding of the issuer and the offering. 

The securities offered by HeartSciences are highly speculative. Investing in these securities involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Investors must understand that such investment could be illiquid for an indefinite period of time. There is no existing public trading market for the Series D Convertible Preferred Stock. HeartScience does not intend to apply for listing of the Series D Convertible Preferred Stock or the common stock purchase warrants on a national securities exchange or quoted on an over the counter market. 

Get Your News

Subscribe and thrive

Snacks provides fresh takes on the financial news you need to start your day. Chartr provides data visualizations on business, entertainment, and society. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.